Pramipexole dihydrochloride (C15-1201-302)

General description

Pramipexole belongs to non-ergoline class and is derived from benzothiazole. It has strong affinity for D2 and D3 receptors (dopamine receptors) compared to other ergoline-derived drugs. However, it does not associate with non-dopamine receptors, for instance adrenergic and serotonin receptors.

Application

Pramipexole dihydrochloride has been used as D2 receptor agonist in dopamine (DA)-depleted striatum slices.

Pramipexole dihydrochloride has been used as a D2-like DR (dopaminergic receptor) agonist in study associated with Parkinson′s disease. It has also been used as a D2/D3 receptor agonist to study risky decision-making in rats.

Biochem/physiol Actions

Pramipexole elicits neuroprotective role and may help in treating depression. It also has a potential to modulate limb movement and may be effective in treating restless legs syndrome.

Pramipexole is a dopamine agonist active at D3 and D2 receptor subtypes. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.

Pramipexole is a therapeutic agent for Parkinson′s disease and restless leg syndrome. It also exhibits antidepressant responses in patients suffering from MDD (major depressive disorder) and bipolar depression.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.